Current concepts in management of pain in children in the emergency department

Baruch S Krauss, Lorenzo Calligaris, Steven M Green, Egidio Barbi

Pain is common in children presenting to emergency departments with episodic illnesses, acute injuries, and exacerbation of chronic disorders. We review recognition and assessment of pain in infants and children and discuss the manifestations of pain in children with chronic illness, recurrent pain syndromes, and cognitive impairment, including the difficulties of pain management in these patients. Non-pharmacological interventions, as adjuncts to pharmacological management for acute pain and anxiety, are described by age and development. We discuss the pharmacological management of acute pain and anxiety, reviewing invasive and non-invasive routes of administration, pharmacology, and adverse effects.

Introduction

Pain is a common symptom in children presenting to emergency departments. Under-treatment of pain (commonly labelled oligoanalgesia) has been frequently reported particularly in younger children, those with cognitive impairment, and children in developing countries. Organisations such as the Joint Commission International have made pain assessment and management a priority issue.1 Initiatives include recording of pain scores, staff education, and quality improvement processes.2–4 Such efforts have fostered advances in the pharmacological and non-pharmacological treatment of pain in children. We review the state of emergency-department pain management in children, including recognition, assessment, and non-pharmacological and pharmacological treatment.

Recognition and assessment of pain

Pain as a presenting complaint for episodic illnesses, acute injuries, or exacerbation of chronic conditions, accounts for up to 78% of emergency department visits.6 Musculoskeletal injuries are common;7–8 27–42% of children sustain a fracture before the age of 16 years.9,11 Other common causes include headache, otalgia, sore throat, and abdominal distress.7,10–13 About half of patients report their pain as moderate to severe.7,15,16 A visit to a noisy, crowded emergency department can be a frightening experience for a child with acute pain, especially if he or she should need a diagnostic or therapeutic procedure. Early and aggressive treatment of pain is recommended, because uncontrolled or severe pain stimuli can lead to hyperalgesia—an enhancement of the pain response (figure 1).7

Recognition and assessment of pain in infants and young children can be difficult because these patients cannot verbalise their pain experience (panel). Spinal reflex responses to mechanical stimulation are exaggerated in young infants, but facial expression is a weak indicator.18 In preverbal children, excessive crying, irritability, poor feeding, position and movement of the arms and legs, and sleep disturbance can indicate pain.19,20

Altered facial expression is also suggestive.9 Physiological variables can also indicate acute pain.19,20

Tools to grade children’s pain are widely recommended;20 they include: physiological measures (heart and respiratory rates, blood pressure), observational and behavioural measures (grading of facial expression, leg movements, activity, crying), self-reporting measures,19 and parents’ report.21 No single element is reliable alone, including pain scoring, so a combination of measures is generally used clinically.21 Physiological measures reflect stress reactions that are not generally correlated with self-reported pain. Behavioural measures can reflect fear and anxiety rather than pain.22 Accordingly, most physicians regard patients’ self-reporting of pain as the gold standard for children old enough to comply effectively.23,24

Several behavioural scales are widely used for infants and non-verbal children, including the face, legs, activity, cry, and consolability scale25 and the Children’s Hospital of Eastern Ontario pain scale.26 Numerical scales are not suitable for younger children, and pictorial-based pain scales are used, such as the

Search strategy and selection criteria

We searched the Cochrane Library, Medline, PubMed, and relevant specialty journals (all from 1980 to January, 2014). We used the search terms “pediatric pain”, “pain assessment”, “pain management”, “chronic pain”, “pain scores”, “pain protocols”, and “emergency department”. We selected publications from the past 15 years with an emphasis on the past 3 years, but we did not exclude commonly referenced and influential older publications. We also searched references of articles identified by our search strategy for related articles. We included four types of studies: randomised controlled trials, observational studies, retrospective studies, and meta-analyses but excluded abstracts and case reports. However, we searched all types of publications, including abstracts and case reports, to find out whether a specific adverse event or complication had been reported. Several review articles, editorials, and book chapters were included because they provide comprehensive overviews that are beyond the scope of this Review.

www.thelancet.com Published online June 19, 2015 http://dx.doi.org/10.1016/S0140-6736(14)61686-X

Division of Emergency Medicine, Boston Children’s Hospital, and Department of Pediatrics, Harvard Medical School, Boston, MA, USA (B S Krauss MD); Institute for Maternal and Child Health, IRCCS Burlo Garofolo, Trieste, Italy (L Calligaris MD, E Barbi MD); and Department of Emergency Medicine, Loma Linda University Medical Center, Loma Linda, CA, USA (Prof S M Green MD)

Correspondence to:
Dr Baruch S Krauss, Division of Emergency Medicine, Boston Children’s Hospital, 300 Longwood Avenue, Boston, MA 02115, USA
baruch.krauss@childrens.harvard.edu
Pain in children with special needs

Pain in children with chronic illness

Acute pain is common in children with chronic illnesses such as sickle cell disease, haemophilia, juvenile idiopathic arthritis, inflammatory bowel disease, hereditary angioedema, cancer, Mediterranean fever, Fabry disease, and Gaucher disease. Some typical features of acute pain (e.g., tachycardia, diaphoresis, facial expression) might not manifest in these children, as they attenuate with time in chronic pain.27 These children and their families often have heightened fear and anxiety related to pain sensitisation30,31 from repeated experiences during which pain was not adequately controlled.31,34 Effective analgesia should be initiated while specific disease-related treatments are sought.

Chronic conditions with recurrent pain

Headache is the most common chronic or recurrent pain in children, followed by abdominal pain and musculoskeletal pain.35 Migraine occurs in up to 10-6% of children between the ages of 5 years and 15 years, and up to 28% of older adolescents.36 Recurrent abdominal pain affects 9–15% of children,37,38 while constipation has a worldwide prevalence of 7–30%39 and is a frequent cause of emergency department visits for abdominal pain.40 Chronic pain can substantially affect the life of the child and family through school absences, poor grades, social withdrawal, and adverse family interactions. Complex regional pain syndrome is a chronic painful disorder characterised by neurogenic inflammation with increased tissue levels of mediators, enhanced peripheral adrenergic sensitivity, with reorganisation of sensory and motor cortex. Most of the scientific literature on complex regional pain syndrome is in adults. This disorder is best treated by interdisciplinary treatment programmes based on a combination of medications (anti-neuropathic drugs such as gabapentin, local anaesthetics, acetaminophen, non-steroidal anti-inflammatory agents, tramadol, and low-dose ketamine), somatic and sympathetic blocks, and cognitive-behavioural and physical therapies. Children admitted with acute on chronic flares should be managed by a paediatric pain management expert.41,42

Pain in children with cognitive impairment

Children with cognitive impairment (e.g., cerebral palsy, metabolic syndromes, genetic diseases) frequently have pain related to specific conditions such as gastro-oesophageal reflux disease with oesophagitis, spasticity with muscle spasm or contractures leading to joint subluxations and dislocations, constipation and faecal impaction, osteopenia with pathological fractures, and dental disease; they can also have pain from trauma, infections, headache, teething, and menses.43 Maladaptive behaviour, decreased functioning, and sleep disorders often result. Cognitively impaired children seem to experience pain more frequently than healthy

---

**Panel: Signs and symptoms of pain in infants and young children**

**Physiological changes**
- Increase in heart rate, respiratory rate, blood pressure, muscle tone
- Oxygen desaturation
- Sweating
- Flushing
- Pallor

**Behavioural changes**
- Change in facial expression (grimacing, furrowing of the brow, nasal flaring, deep nasolabial groove, curving of the tongue, quivering of the chin)
- Finger clenching
- Thrashing of limbs
- Writhing
- Back arching
- Head banging
- Poor feeding
- Sleep disturbance
- Pseudoparalysis

Wong-Baker FACES, and OUCHER pain scales. Children older than about 8 years can generally comply with visual analogue scales and verbal numerical scales, the tools used in adults.38
children, with the more severely impaired experiencing the most pain.44,45 Severely affected children cannot verbalise their pain and can present with atypical pain responses, such as a full-blown smile (with or without laughter) or the freezing phenomenon (the face not moving for several seconds). Reduced interaction, search for comfort or physical closeness, shivering, pallor, sweating, sharp breath, and breath-holding are common manifestations of pain in this population.46 Some pain features are particular to specific syndromes. Children with Down’s syndrome can show delayed expression of pain and have difficulty in localising it.47,48 Children with autism spectrum disorders respond in the same way as non-autistic children do to noxious stimuli, but they tend to recover more slowly.49,50 Facial and leg movements can be impaired in cerebral palsy, and recognition of pain is therefore complex.

Specific measurement tools that take into account idiosyncratic pain behaviours, such as verbal outbursts, tremors, increased spasticity, jerking movements, and changes in respiratory pattern, can be used for this population. The non-communicating child’s pain checklist—postoperative version,51,52 an observational scale based on manifestations that are deemed to be physiological or behavioural indicators of pain, is widely used for children from age 3 years up to 18 years. Although regarded by experienced operators to be the most reliable and easiest scale to use for children with cognitive impairment,52 it can be time-consuming and difficult to administer by staff unfamiliar with its use.

Analgetic therapy in children with cognitive impairment and cerebral palsy should take into account factors that could alter doses, duration of treatment, and side-effects. Spasticity-related pain is treated with baclofen or diazepam.53 Malnutrition and dehydration can increase the risk of adverse effects from paracetamol and non-steroidal anti-inflammatory drugs (NSAIDs).54 Some anticonvulsants (carbamazepine, phenobarbitral, phenytoin, primidone) can increase the risk of paracetamol toxicity. Opioid adverse effects can exacerbate motor impairment, spasticity, constipation, and chronic lung disease.41,55

Somatisation
Psychosomatic symptoms account for 8–10% of primary care visits and are a common reason for assessment in the emergency department.56 A somatoform disorder is characterised by symptoms that suggest physical illness but cannot be explained by a general medical condition and are not attributable to a specific mental disorder.57 Somatoform disorders are most common in adolescents, and patients perceive their pain as real and recurrent. Suspicion of somatoform pain is strengthened by the presence of vague and changeable description and location of pain, selective avoidance of unpleasant activities, a temporal relation to a stressful event, related anxiety and depression, difficulties at school, and a family history of somatisation disorders. School refusal, bullying, depression, child abuse, and eating disorders can all present as somatoform pain.58 Suspicion of somatisation should prompt consultation with the primary-care provider and a plan for outpatient follow-up; in some cases, hospital admission with social work and psychiatric assessment might be necessary.

Malingering
Malingering is defined as feigning an illness, or consciously exaggerating symptoms of a real illness, to derive personal gain; it should be suspected when there is a discrepancy between history and findings on physical examination or between symptoms and the patient’s anxiety.57 Suspicion is raised by the presence of a symptom shown during the medical examination, a secondary benefit, a loss of school days, an association with a stressful event, or poor compliance with investigations and treatment. Clinicians should consider malingering in their differential diagnosis to avoid unnecessary investigations (eg, CT for abdominal pain). Malingering should prompt consultation with the primary care provider and a plan for outpatient follow-up.

Non-pharmacological approaches for acute pain and anxiety
Physical comfort measures and distracting activities
Psychological, behavioural, and physical interventions, stratified by age and development, can be used as adjuncts to pharmacological management.59-64 In children, disorders causing acute pain are often accompanied by anxiety and distress. A stepwise approach to managing acute pain and anxiety combines pharmacological and non-pharmacological interventions as integrated treatment (figure 1).

Non-pharmacological approaches can be divided into two general categories: physical comfort measures and distracting activities (figure 2).64 Physical comfort measures are specific interventions for neonates, infants, and young children. Neonates and infants have a positive physiological response (lowering of pain scores, cry duration, and heart rate variation) to oral stimulation as well as physical contact or touch during painful procedures (venepuncture, heel lancing).

Preschool children benefit from touch and various distracting activities. Application of heat or cold for minor injuries or burns is appropriate for school-age and older children and adolescents, but it should be carefully supervised by parent or clinician in preschool children and those who are non-verbal or have difficulty in communicating.

Passive and interactive distracting activities can be used in children of all ages and developmental levels; they include bubble blowing, lighted wands, sound and music, controlled deep breathing, art, puppets, imitation play, interactive games, books, guided imagery, and hypnosis.
Non-pharmacological interventions are especially helpful when cooperation is necessary but pharmacological management is not feasible. Physical examination and common procedures such as venepuncture and intravenous cannulation can be difficult to accomplish in distressed young children because they cannot control their apprehension.65–67 Topical anaesthetics control pain but have little effect on distress in a child expecting a needle. Forceful immobilisation, widely used for young children when pharmaceutical intervention is not practicable, can be frightening and can further escalate the already high degree of anxiety, leading to apprehension of medical staff and future medical treatment.68,69 Understanding of neurodevelopmental principles provides a practical framework for clinicians to manage acute anxiety and distress in young children (aged 2–5 years) because the ability to control distress necessitates the maturation of specific neural structures.65,66,70 Young children have difficulty in gaining control of fear because the connectivity between frontal-lobe structures and the rest of the brain is not fully mature; this connectivity facilitates the control of intense affective states.65,66,70 Young children who are fearful have compromised ability to use the language of others to reassure themselves and therefore have difficulty cooperating.65,67,68 Furthermore, young children have difficulty in relating their past experience to what is happening in the present.67 To understand the meaning of such phrases as “it will only hurt for a minute” or “almost done”, the child has to recall past events with a short duration. Thus, young children are not able to use this information to control their distress.

Because young children are cognitively immature, physical comfort measures and distraction activities are more effective than is verbal reasoning in helping to control their distress. Children do not have sufficient cognitive development to understand the perspective of strangers trying to reassure them until the age of 5–7 years.65–67,70–72

Role of parents

Parents can be active participants in helping their child to cope with procedures and can assist the clinician by engaging the child in an activity of interest, shifting attention away from the examination or procedure. However, parents’ ability to assist the clinician depends on their own level of anxiety. A very anxious parent, or one who has other children to take care of, will find it difficult to assist in helping the sick child to cope with the examination or procedure.

Strategies for managing parents vary according to their degree of anxiety: having parents leave the room before the start of the examination or procedure (for those who are extremely anxious or emotionally distraught); having parents simply observe the procedure; or having parents actively assist by helping comfort and calm their child. Play therapists and child life specialists can be especially helpful in working with the parents and the child to relieve anxiety and improve cooperation.

Clinicians should be aware of parental input (to the child) before arrival in hospital and be prepared to recognise, and undo if necessary, counterproductive parental suggestions, especially if they result in a high degree of anxiety and distress. Many parents, in an attempt to lessen the child’s anxiety and increase coping capability, will tell the child that he or she will be getting a small needle and the procedure will only hurt for a minute (or words to that effect). In this situation, the clinician might be greeted by the child in obvious distress about the possibility of an injection.

Parents should be prepared and coached. Clinicians should discuss with parents, before the examination or procedure and out of earshot of the child, what will happen and how the parents can help their child to cope. Parents should be instructed in the use of language-based coping skills (use of developmentally specific words and phrases, encouragement, praise) and distraction activities and to avoid vague or negative language, apology, global reassurance, criticism, or the use of potentially frightening terms (figure 3).65,67 Assignment of these tasks to parents serves as a
distraction for them, probably lessening the personal anxiety that they transmit to the child. Words or phrases that are helpful to one child might be threatening to another; parents and health-care providers should select their language carefully.97

Pharmacological treatment of acute pain

Analgesic therapy

Analgesic therapy is warranted whenever non-pharmacological approaches are insufficient, or when they are unlikely to achieve the needed pain relief when given alone. We present various recommended options in tables 1 and 2. Inhaled nitrous oxide and parenteral ketamine are often administered for sedation and analgesia during procedures; however, we do not discuss these drugs further here given the limited published experience for non-procedural analgesia in children.

Routes of administration

The oral and intranasal routes are fast and well tolerated for initial pain therapy, if they are not contraindicated by the clinical situation (ie, if fasting is indicated or the child has nasal trauma or obstruction). The intranasal route has the advantage of quicker onset and higher bioavailability. Severe pain is best treated intravenously, because the ability to titrate to pain relief rapidly generally outweighs the additional stress and pain caused by achieving intravenous access.

Mild pain

Paracetamol is extremely safe at therapeutic doses96 and can readily be used for mild pain alone or with other agents for moderate to severe pain. On the basis of pharmacokinetics, a higher initial loading dose can be considered (table 1),97 as long as continued therapy will not exceed the daily maximum dose. In some countries, an intravenous form of paracetamol is available and is particularly valuable when a child is vomiting. Paracetamol is very unlikely when intravenous opioids are titrated carefully and seems to be safe.108,109

Alternatives to paracetamol for mild pain are NSAIDs such as ibuprofen and naproxen. NSAIDs can cause adverse gastrointestinal and renal effects; however, they are uncommon in children.98,99 Owing to its association with Reye’s syndrome, aspirin should be avoided as an analgesic except for specific rheumatological disorders.

Coadministered paracetamol and ibuprofen can be superior to either agent alone.98 Some parents and clinicians administer paracetamol and ibuprofen simultaneously in alternating doses; this practice seems safe but might not provide superior pain relief to either agent alone.

Oral sucrose decreases crying time in infants aged 1–12 months who are undergoing needle-related procedures, and it is of course safe.101,102 Sucrose does not seem to be effective in children older than a year.103

Tramadol, an opioid-related analgesic, has not been well studied in children. It seems to be less potent than traditional opioids, but it causes less respiratory depression and sedation as well as other adverse effects than other opioids do. It can lower the seizure threshold and has been associated with serotonin syndrome. It should be avoided in patients with a history of epilepsy and those receiving stimulant or serotonergic drugs.81,104

Moderate pain

Moderate pain warrants more potent therapy than paracetamol or NSAIDs alone, such as an oral opioid. Inhaled diamorphine or fentanyl can also provide similar initial pain relief to intravenous opioids.85–89,105

Codeine is no longer recommended owing to its differential metabolism, with low efficacy in poor metabolizers and rare reports of life-threatening or fatal respiratory depression in ultra-rapid metabolizers.86,107

Severe pain

In children with severe pain, intravenous access should be established as soon as possible; titrated opioids should then be given. Oral or nasal opioids can be given before intravenous cannulation. Inhaled methoxyflurane (available in the UK, Australia, and New Zealand) has also been used for rapid pain relief in the prehospital setting and seems to be safe.98,109

Should opioid therapy result in drowsiness or mild respiratory depression, further doses should be withheld and the child monitored carefully and stimulated as needed. Serious respiratory depression is unlikely when intravenous opioids are titrated carefully with standard doses; however, whenever they are administered, resuscitation and monitoring equipment should be immediately available, as should the reversal agent naloxone.
## Route and dose

### Mild pain

<table>
<thead>
<tr>
<th>Medicine</th>
<th>Intravenous</th>
<th>Oral</th>
<th>Oral</th>
<th>Oral</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Paracetamol</strong></td>
<td></td>
<td>&lt;10 kg: 7.5 mg/kg every 4–6 h, maximum 30 mg/kg daily</td>
<td>≥10 kg: 15 mg/kg every 6 h, maximum 50 mg/kg daily or 4000 mg/day</td>
<td>Oral</td>
</tr>
<tr>
<td></td>
<td></td>
<td>&lt;60 kg: 10–15 mg/kg every 4 h, maximum 100 mg/kg daily</td>
<td>≥60 kg: 650-1000 mg every 4 h, maximum 4000 mg/day</td>
<td>Oral</td>
</tr>
<tr>
<td><strong>Ibuprofen</strong></td>
<td></td>
<td>Infants: 4-10 mg/kg every 6–8 h, maximum 40 mg/kg daily</td>
<td>≥60 kg: 400-800 mg every 6–8 h, maximum 3200 mg/day</td>
<td>Oral</td>
</tr>
<tr>
<td></td>
<td></td>
<td>≥60 kg: 6–10 mg/kg every 6–8 h, maximum 40 mg/kg daily</td>
<td>≥60 kg: 6–10 mg/kg every 6–8 h, maximum 40 mg/kg daily</td>
<td>Oral</td>
</tr>
<tr>
<td><strong>Naproxen</strong></td>
<td></td>
<td>&gt;2 years: 5–7 mg/kg every 8–12 h</td>
<td>≥60 kg: 250–500 mg every 12 h, maximum 1000 mg/day</td>
<td>Oral</td>
</tr>
<tr>
<td></td>
<td></td>
<td>&lt;60 kg: 10–15 mg/kg every 4 h, maximum 100 mg/kg daily</td>
<td>≥60 kg: 6–10 mg/kg every 6–8 h, maximum 40 mg/kg daily</td>
<td>Oral</td>
</tr>
</tbody>
</table>

### Moderate pain

<table>
<thead>
<tr>
<th>Medicine</th>
<th>Oral</th>
<th>Oral</th>
<th>Oral</th>
<th>Oral</th>
<th>Oral</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Hydromorphone</strong></td>
<td>≤6 months: 0.025–0.05 mg/kg every 4–6 h</td>
<td>&lt;50 kg: 0.1–0.2 mg/kg every 4–6 h</td>
<td>≥50 kg: 5–10 mg every 4–6 h</td>
<td>Oral</td>
<td></td>
</tr>
<tr>
<td>Hydrocodone (with paracetamol)</td>
<td>Oral</td>
<td>Oral</td>
<td>Oral</td>
<td>Oral</td>
<td>Oral</td>
</tr>
<tr>
<td><strong>Oxycodone</strong></td>
<td>≤6 months: 0.025–0.05 mg/kg every 4–6 h</td>
<td>&lt;50 kg: 0.1–0.2 mg/kg every 4–6 h</td>
<td>≥50 kg: 5–10 mg every 4–6 h</td>
<td>Oral</td>
<td></td>
</tr>
<tr>
<td></td>
<td>≥50 kg: 5–10 mg every 4–6 h</td>
<td>Oral</td>
<td>Oral</td>
<td>Oral</td>
<td>Oral</td>
</tr>
<tr>
<td><strong>Hydromorphone</strong></td>
<td>Infants &gt;6 months and &gt;10 kg: start 0.03 mg/kg every 4 h</td>
<td>Children &lt;50 kg: 0.03–0.08 mg/kg every 3–4 h</td>
<td>Children ≥50 kg: 2–4 mg every 3–4 h</td>
<td>Oral</td>
<td></td>
</tr>
<tr>
<td></td>
<td>≥6 months: 0.1–0.2 mg/kg every 4–6 h</td>
<td>≥60 kg: 15–30 mg/kg every 6 h</td>
<td>Oral</td>
<td>Oral</td>
<td>Oral</td>
</tr>
<tr>
<td><strong>Ketorolac</strong></td>
<td>≥50 kg: 20 mg initially, then 10 mg every 4–6 h, maximum 40 mg/day</td>
<td>Oral</td>
<td>Oral</td>
<td>Oral</td>
<td>Oral</td>
</tr>
<tr>
<td></td>
<td>Intravenous</td>
<td>≥1 month and &lt;2 years: 0.5 mg/kg every 6–8 h</td>
<td>≥16 years: 0.5 mg/kg up to 15 mg every 6 h</td>
<td>≥16 years: 50–100 mg every 4–6 h, maximum 400 mg/day</td>
<td>Oral</td>
</tr>
<tr>
<td></td>
<td>≥16 years: 0.5 mg/kg up to 30 mg every 6 h</td>
<td>Oral</td>
<td>Oral</td>
<td>Oral</td>
<td>Oral</td>
</tr>
<tr>
<td><strong>Tramadol</strong></td>
<td>4–16 years: 1–2 mg/kg up to 100 mg every 4–6 h, maximum the lesser of 8 mg/kg daily or 400 mg/day</td>
<td>≥16 years: 50–100 mg every 4–6 h, maximum 400 mg/day</td>
<td>Oral</td>
<td>Oral</td>
<td>Oral</td>
</tr>
<tr>
<td></td>
<td>≥16 years: 50–100 mg every 6 h</td>
<td>Intravenous</td>
<td>Intravenous</td>
<td>Oral</td>
<td>Oral</td>
</tr>
<tr>
<td><strong>Fentanyl</strong></td>
<td>≥4 years: 2 mg/kg up to 100 mg every 4–6 h</td>
<td>Oral</td>
<td>Oral</td>
<td>Oral</td>
<td>Oral</td>
</tr>
<tr>
<td></td>
<td>Oral</td>
<td>Oral</td>
<td>Oral</td>
<td>Oral</td>
<td>Oral</td>
</tr>
<tr>
<td><strong>Diamorphine</strong></td>
<td>≥6 months: 0.1 mg/kg aerosol</td>
<td>Oral</td>
<td>Oral</td>
<td>Oral</td>
<td>Oral</td>
</tr>
<tr>
<td></td>
<td>Oral</td>
<td>Oral</td>
<td>Oral</td>
<td>Oral</td>
<td>Oral</td>
</tr>
<tr>
<td><strong>Fentanyl</strong></td>
<td>≥6 months: 1–2 μg/kg up to 50 μg aerosol (volumes &gt;0.2 mL divided between nostrils)</td>
<td>Oral</td>
<td>Oral</td>
<td>Oral</td>
<td>Oral</td>
</tr>
</tbody>
</table>

### Severe pain

<table>
<thead>
<tr>
<th>Medicine</th>
<th>Intravenous</th>
<th>Oral</th>
<th>Oral</th>
<th>Oral</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Morphine</strong></td>
<td>≤6 months: titrate to pain control, with usual effective dose 0.025–0.050 mg/kg, typically repeat every 2–4 h</td>
<td>&gt;16 months and &gt;50 kg: titrate to pain control, with usual effective dose 2–5 mg, typically repeat every 3–4 h</td>
<td>Oral</td>
<td>Oral</td>
</tr>
<tr>
<td></td>
<td>≥6 months and &gt;50 kg: titrate to pain control, with usual effective dose 0.2–0.5 mg/kg; typically repeat every 3–4 h</td>
<td>≥50 kg: titrate to pain control, with usual effective dose 2–5 mg, typically repeat every 3–4 h</td>
<td>Oral</td>
<td>Oral</td>
</tr>
<tr>
<td><strong>Fentanyl</strong></td>
<td>≤6 months: titrate to pain control, with usual effective dose 1–4 μg/kg; typically repeat every 2–4 h</td>
<td>≥6 months and &gt;50 kg: titrate to pain control, with usual effective dose 1–2 μg/kg; typically repeat every 30–60 min</td>
<td>Intravenous</td>
<td>Intravenous</td>
</tr>
<tr>
<td></td>
<td>≥50 kg: titrate to pain control, with usual effective dose 50–100 μg; typically repeat every 1–2 h</td>
<td>≥50 kg: titrate to pain control, with usual effective dose 1–2 μg/kg; typically repeat every 30–60 min</td>
<td>Intravenous</td>
<td>Intravenous</td>
</tr>
<tr>
<td><strong>Hydromorphone</strong></td>
<td>Infants &gt;6 months and &gt;10 kg: titrate to pain control, starting with 0.01 mg/kg every 3–6 h</td>
<td>Children &lt;50 kg: titrate to pain control, with usual effective dose 0.015 mg/kg; typically repeat every 3–6 h</td>
<td>Children ≥50 kg: titrate to pain control, with usual effective dose 1 mg, typically repeat every 2–3 h</td>
<td>Intravenous</td>
</tr>
</tbody>
</table>

Changes in dosing might be indicated according to the clinical situation. Intravenous doses should be administered slowly. Patients with chronic pain might need more frequent and higher doses. All doses are shown for immediate-release preparations. Optimum dosing strategies for obese children remain undefined; some clinicians calculate on the basis of ideal bodyweight whereas others select a point somewhere between ideal and actual bodyweight. *Maximum 75 mg/kg daily in infants, 60 mg/kg daily in term neonates.

Table 1: Systemic pharmacological management of acute pain in children
Adverse effects of the histamine-releasing opioids (morphine, hydromorphone), including nausea, vomiting, and pruritus, can be treated with antiemetics and antihistamines. Decreases in blood pressure from morphine or hydromorphone are generally not clinically significant in otherwise healthy children. Meperidine is no longer used in most settings, because it has no advantages over other opioids and has a metabolite that can cause seizures.

Prehospital pain
Management of paediatric pain in ambulances is constrained by provider training and experience, limited available analgesic agents, and the competing management priorities of transport to the hospital.

Acute exacerbations of chronic pain
Many children with sickle-cell disease, cancer, or other recurrent or chronic pain syndromes have opioid tolerance, and intravenous administration is preferred so that the higher doses generally needed for pain relief can be rapidly titrated. In patients with sickle-cell vaso-occlusive crisis necessitating hospital admission, patient-controlled analgesia can be initiated in the emergency department after initial pain control has been achieved.

Topical anaesthesia
Topical anaesthetics applied to intact skin can effectively diminish the pain of phlebotomy, intravenous cannulation, or lumbar puncture (table 2). Tetracaine works faster than lidocaine plus prilocaine (EMLA cream) and seems to provide superior pain relief. Ethyl chloride (coolant) spray has shown mixed results for topical anaesthesia and is not preferred to the agents in table 2.

A locally prepared solution or gel containing lidocaine, epinephrine, and tetracaine (table 2) can be applied directly onto small wounds to provide partial or complete local anaesthesia.

Procedures
Children with painful conditions that necessitate procedures (eg, displaced fractures, abscesses, joint effusions) should first receive effective analgesia by one of the routes discussed (table 1). Many will also need procedural sedation with midazolam, nitrous oxide, ketamine, propofol, or other agents; such sedation practice has been detailed elsewhere and is beyond the scope of this review.

Standing protocols
Nurse-driven triage protocols for pain assessment and management allow rapid initiation of pharmacological pain relief along with non-pharmacological measures such as distraction activities, positions of comfort, ice, and immobilisation. We encourage the adoption of standing protocols to permit triage nurses to administer analgesics rapidly to children in pain, and to apply topical anaesthesia to appropriate skin locations for those likely to need laceration repair, intravenous cannulation, or lumbar puncture.

<table>
<thead>
<tr>
<th>Topical pharmacological management of acute pain in children</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Dose</strong></td>
</tr>
<tr>
<td>-----------------------------</td>
</tr>
<tr>
<td><strong>Intact skin</strong></td>
</tr>
<tr>
<td>Lidocaine 2.5% and prilocaine 2.5% (EMLA cream)</td>
</tr>
<tr>
<td>Lidocaine 70 mg and tetracaine 70 mg (Synephrine patch)</td>
</tr>
<tr>
<td>Tetracaine 4% (Ametop)</td>
</tr>
<tr>
<td><strong>Wounds</strong></td>
</tr>
<tr>
<td>Lidocaine, epinephrine, tetracaine (LET)</td>
</tr>
</tbody>
</table>

*Also referred to as AIL on the basis of alternative names for the constituents: adrenaline, lignocaine, amethocaine.
These mixtures are locally made by hospital formularies, with a common formula being lidocaine 4% plus epinephrine 0.1% plus tetracaine 0.5%. The cocaine-based formulation was historically avoided on wounds of digits, ears, penis, nose, mucous membranes, close to the eye, or deep wounds involving bone, cartilage, tendon, or vessels. The lidocaine-based formulation can be used in such settings.

Future directions
Future initiatives in emergency-department paediatric pain management will focus on developing condition-specific protocols to optimise pain recognition, assessment, and management, especially for children with cognitive impairment, recurrent pain syndromes, and chronic illness. How can we know when we have successfully provided sufficient analgesia, and when our efforts remain inadequate? When does anxiety predominate over pain such that anxiolytic agents might be more effective than analgesics? What are safe and effective methods of providing rapid pain relief on arrival in the emergency department by use of nurse-driven triage protocols? How can we safely improve the efficacy of non-invasive routes of administration (oral, sublingual, intranasal)? Is there a role for tramadol or ketorolac in the management of acute pain in children? How can we apply pharmacogenomics to individualise treatment and decrease related adverse events? Can we safely expand the use of patient-controlled analgesia to selected populations (eg, sickle-cell disease, cancer-related pain)?

Contributors
BSK, LC, SMG, and EB contributed equally to drafting and revising the report, including the scientific literature search, figures, tables, and references. BSK takes responsibility for the review as a whole.

Declaration of interests
We declare no competing interests.

Acknowledgments
We are grateful to Professor Jerome Kagan for his contribution to the non-pharmacological approaches for acute pain and anxiety section.


